Long-term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets in the CLARITY and CLARITY Extension Studies

被引：0
|
作者：
Giovannoni, G. [1 ]
Comi, G. [2 ,3 ]
Rammohan, K. [4 ]
Rieckmann, P. [5 ,6 ]
Vermersch, P. [7 ]
Dangond, F. [8 ]
Keller, B. [9 ]
Jack, D. [9 ]
机构：
[1] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England
[2] Univ Vita Salute San Raffaele, Dept Neurol, Osped San Raffaele, Milan, Italy
[3] Univ Vita Salute San Raffaele, Inst Expt Neurol, Osped San Raffaele, Milan, Italy
[4] Univ Miami, Sch Med, MS Res Ctr, Miami, FL USA
[5] Med Pk Loipl, Ctr Clin Neuroplast, Erlangen, Germany
[6] Univ Erlangen Nurnberg, Erlangen, Germany
[7] Univ Lille, INSERM, CHU Lille, FHU Imminent,U1172, Lille, France
[8] EMD Serono Res & Dev Inst Inc, Billerica, MA USA
[9] Merck KGaA, Darmstadt, Germany
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2020年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPR3084
引用
收藏
页码：468 / 468
页数：1
相关论文
共 50 条
  • [1] Long-term disease stability assessed by the expanded disability status scale in patients treated with cladribine tablets in the clarity and clarity extension studies
    Giovannoni, G.
    Comi, G.
    Rammohan, K.
    Rieckmann, P.
    Vermersch, P.
    Dangond, F.
    Keller, B.
    Jack, D.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [2] Long-term disease stability assessed by the expanded disability status scale in patients treated with Cladribine tablets in the CLARITY and CLARITY extension studies
    Giovannoni, G.
    Comi, G.
    Rammohan, K.
    Rieckmann, P.
    Vermersch, P.
    Dangond, F.
    Keller, B.
    Jack, D.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 873 - 874
  • [3] Long-term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets in the CLARITY and CLARITY Extension Studies
    Giovannoni, G.
    Comi, G.
    Rammohan, K.
    Rieckmann, P.
    Vermersch, P.
    Dangond, F.
    Keller, B.
    Jack, D.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP62 - NP63
  • [4] Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies
    Gavin Giovannoni
    Giancarlo Comi
    Kottil Rammohan
    Peter Rieckmann
    Fernando Dangond
    Birgit Keller
    Dominic Jack
    Patrick Vermersch
    Advances in Therapy, 2021, 38 : 4975 - 4985
  • [5] Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies
    Giovannoni, Gavin
    Comi, Giancarlo
    Rammohan, Kottil
    Rieckmann, Peter
    Dangond, Fernando
    Keller, Birgit
    Jack, Dominic
    Vermersch, Patrick
    ADVANCES IN THERAPY, 2021, 38 (09) : 4975 - 4985
  • [6] Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets
    Giovannoni, Gavin
    Comi, Giancarlo
    Rammohan, Kottil
    Rieckmann, Peter
    Vermersch, Patrick
    Dangond, Fernando
    Keller, Birgit
    Jack, Dominic
    NEUROLOGY, 2020, 94 (15)
  • [7] Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies
    De Stefano, Nicola
    Sormani, Maria Pia
    Giovannoni, Gavin
    Rammohan, Kottil
    Leist, Thomas
    Coyle, Patricia K.
    Dangond, Fernando
    Keller, Birgit
    Alexandri, Nektaria
    Galazka, Andrew
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (01) : 111 - 120
  • [8] Severity and frequency of relapses in patients with relapsing-remitting MS treated with cladribine tablets in CLARITY and placebo in CLARITY extension
    Schippling, S.
    Sormani, M. P.
    De Stefano, N.
    Giovannoni, G.
    Dangond, F.
    Galazka, A.
    Keller, B.
    Alexandri, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 857 - 858
  • [9] Absolute lymphocyte counts in patients with relapsing multiple sclerosis (RMS) treated with cladribine tablets 3.5 mg/kg in the CLARITY and CLARITY Extension studies
    Soelberg-Sorensen, P.
    Dangond, F.
    Hicking, C.
    Giovannoni, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 412 - 412
  • [10] Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study
    Comi, Giancarlo
    Cook, Stuart
    Rammohan, Kottil
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Adeniji, Abidemi K.
    Dangond, Fernando
    Giovannoni, Gavin
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11 : 1 - 11
12345